PSX Options Sentiment Flips Bullish Ahead of October 28 Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Phillips 66 enters its October 28 earnings date with options traders having turned notably more bullish over the past week, even as short sellers quietly added to positions.
The clearest shift is in options. The put/call ratio has dropped to 0.83, more than two standard deviations below its 20-day average of 0.95, placing it near the most call-heavy reading of the past year. The 52-week low on the PCR is 0.71, so the current reading is approaching that bullish extreme. That marks a sharp reversal from early September, when the ratio was running above 1.15, reflecting heavier demand for downside protection. The borrow market adds little drama. Availability remains extraordinarily loose, with 355 million shares available against roughly 5.6 million sold short. Cost to borrow holds at 0.38%, barely changed on the week, and short interest at 1.4% of free float is simply not a primary driver of this stock's narrative.
Short interest itself has edged up about 5% over the past week to 5.6 million shares, recovering from a drop earlier in October when the figure briefly touched 5.3 million. The monthly picture shows a net decline of roughly 4.5%, so the week-on-week drift higher is a minor consolidation within a broader retreat. PSX fell 0.6% on the week, a relatively contained move compared with peers: VLO shed 5%, PBF fell nearly 9%, and DINO dropped 2.3%. The month has been kinder, with PSX up 6.6% over 30 days.
The analyst picture has moved since the last note on this stock. The mean price target has risen to $285, from around $276 a week ago, but the stock at $291 continues to trade above consensus. Wells Fargo remains the most constructive voice at $345 Overweight, and Goldman Sachs holds Neutral with a $274 target. The range of views is wide, from Evercore ISI at $250 to Wells Fargo at $345, reflecting genuine disagreement about how much credit to give the WRB acquisition synergies and whether refining capture rates can hold near 95%. EPS momentum factor scores rank in the 89th and 93rd percentiles on 30-day and 90-day horizons respectively, and the dividend score ranks in the 94th percentile, numbers that reflect the stock's sharp year-to-date run. The EV/EBITDA multiple of 7.3x has compressed about 0.9x over 30 days, even as the stock climbed, suggesting earnings estimates have risen faster than the share price.
Elliott Management's 4.8% stake, last disclosed as of June 30, remains on the register. A Schedule 13D filed in April by an entity called Link Co disclosed a 10% position, though this filing dates from April 3 and carries only one filing. As with all 13D/G stakes, positions are as last disclosed around the 5% threshold, and a holder dropping below 5% may not file again. The Vanguard entities collectively account for roughly 12.7% of shares outstanding across their various vehicles, with BlackRock holding a further 8.5%.
The prior earnings reaction is worth noting without reading too much into it. The August 5 print produced a near-flat one-day move of minus 0.2%, followed by a strong five-day gain of 9.6%. With the stock already trading above the mean analyst target and options traders positioned more bullishly than at any point in months, the October 28 report is the next concrete test of whether the refining margin story and WRB integration progress can keep pace with a share price that has already moved a long way.
Stocks in this article
See the live data behind this article on ORTEX.
Open PSX on ORTEX →How this article was generated
- Generated
- 21 Oct 2026, 19:57
- Data as of
- 21 Oct 2026, 19:56
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.